Randomized trials to optimize treatment of multidrug-resistant tuberculosis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 17988168.
- Also identified by PMC identifier 2062482.
- Licence recorded as CC0.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The time is now right for randomized trials of MDR-TB, say the authors, as the expansion of MDR-TB programs provides the setting in which trials can be implemented.
Medical subject headings
- Antitubercular Agents
- Extensively Drug-Resistant Tuberculosis
- Tuberculosis, Multidrug-Resistant